Sign Up
OverviewAPI
Centessa Pharmaceuticals presents preclinical data supporting the potential of ORX750, its investigational orexin receptor 2 (OX2R) agonist, for the treatment of narcolepsy and other sleep-wake disorders. The data shows effectiveness in promoting wakefulness and reducing cataplexy at low doses in animal models, suggesting potential for broader sleep-wake disorders. Centessa plans to initiate clinical development in the future.

Ask a question